期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

长效干扰素治疗慢性丙型肝炎的研究进展 被引量：3

下载PDF
导出
摘要 α-干扰素是治疗慢性丙型肝炎的基本药物,但是应用α-干扰素单一疗法的治疗终末病毒应答率只有30%左右,持续病毒应答率仅约10%.
作者 张福奎 周焕明 贾继东 王宝恩
机构地区 首都医科大学附属北京友谊医院肝病中心 滕州市中心人民医院消化内科
出处 《临床肝胆病杂志》 CAS 北大核心 2003年第1期5-7,共3页 Journal of Clinical Hepatology
关键词 慢性丙型肝炎 长效干扰素 治疗 进展 聚乙二醇化干扰素 临床应用 利巴韦林 疗效
分类号 R512.6 [医药卫生—内科学]
  • 相关文献

参考文献14

  • 1[1]McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha - 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].N EngJ Med, 1998, 339:1485- 1492.
  • 2[2]Saracco G, Borghesio E, Mesina P, etal. Prolonged treatment (2 years)with different doses (3 versus 6 MU) of interferon alpha- 2b for chronic hepatitis C. Results of a multicenter randomized trial [J]. J Hepatol,1997, 27:56-62.
  • 3[3]Roberts MJ, Harris JM. Attachment of degradable poly (ethylene glycol)to proteins has the potential to increase therapeutic efficacy[J]. J Pharm Sci, 1998, 87:1440- 1445.
  • 4[4]Zeuzem S. Clinical implications of hepatitis C viral kinetics[J].J Hepatol, 1999, 31(Suppll):61-64.
  • 5[5]Neumann AU, Lam NP, Dahari H, etal. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon - α therapy [J]. Science,1998, 282:103 - 107.
  • 6[6]Monkarsh SP, Ma Y, Aglione A, etal. Positional isomers of monopegy-lated interferon alpha -2a: isolation, characterization, and biological ac-tivity[J].Anal Biochem, 1997, 247:434-440.
  • 7[7]Zeuzam S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a[J].Gastroenterology, 2001, 120:1438 - 1447.
  • 8[8]Reddy KR, Wright TL, Pockros PJ, etal. Efficacy and safety of pegylated (40- kd) interferon alpha- 2a compared with interferon alpha- 2a in noncirrhotc patients with chronic hepatitis C[J].Hepatolgy, 2001, 33:433 - 438.
  • 9[9]Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa- 2a in patients with chronic hepatitis C [J].N Engl J Med, 2000, 343:1666-1672.
  • 10[10]Lindsay KL, Trepo C, Heintges T, et al. A randomized, double- blind trial comparing pegylated interferon alfa- 2b to interfern alfa- 2b as inirial treatment for chronic hepatitis C[J]. Hepatology, 2001,34: 395 -403.

同被引文献15

  • 1马秀云.长效干扰素的相关不良反应[J].药物不良反应杂志,2004,6(5):312-315. 被引量：13
  • 2张鸿飞,杨晓晋,朱世殊,董漪,陈大为,贾文峥,徐志强,毛远丽,唐红梅.聚乙二醇α干扰素治疗54例小儿慢性丙型肝炎报道[J].中华实验和临床病毒学杂志,2005,19(2):185-187. 被引量：16
  • 3鞠洋,路莉,吴勇杰,高明堂,李文广,闵光宁.ELISA法研究新型重组人肿瘤坏死因子在小鼠体内的药代动力学[J].中国药理学通报,2005,21(7):847-851. 被引量：6
  • 4曹振环（编译）.24周长效干扰素联合利巴韦林是治疗HCV基因2型和3型的最佳方案[J].传染病网络动态,2007(9):5-5. 被引量：1
  • 5Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C[J].N Eng 1 Jmed, 2000,J 343 (23) : 1666-1672.
  • 6Osbom B L, Olsen H S, Nardelli B, et al. Phar-macokinetic and pharmacodynamic studies of a human serum albumin-Interferon-α Fusion protein in cynomolgus monkeys[ J]. J Pharmacol Exp Ther, 2002,303 (2) : 540 - 8.
  • 7Bailon P, Palleroni A, Schaffer C A, et al. Rational design of a potent, long-lasting form of interferon : A 40 kDa branchedpolyethylene glycol-conjugated interferon α2a for the treatment of Hepatitis C [ J ]. Bioconjug Chem,2001,12 (2) : 195 - 202.
  • 8Peoinsky R B,Lepage D J, Gil A,et al. Improved Pharmacokinetic propertiesof a polyethylene glycol-modified form of in-terferon-β-1a with preserved in vitro bioactivity[ J]. J Pharmacol Exp Ther, 2001,297(3 ) :1059 -66.
  • 9HGS press release. Human Genome clinical trial of albuferon^TM in treatment-naive patients with chronic hepatitis C [ R ]. February 16, 2005.
  • 10Balan V . Safety, pharmacokinetics and pharmacodynamic results of higher doses of Albuferon (tm) in a phase 1/2 single and double dose-escalation study in treatment experienced subjects with chronic hepatitis C[ R]. 39th Annual Meeting of the European Association for the Study of the Liver, Berlin. April 15, 2004.

引证文献3

二级引证文献10

临床肝胆病杂志
2003年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部